Delving into the Latest Updates on SLC-3010 with Synapse

Overview

Basic Info

Drug Type

Antibody-cytokine conjugate

Synonyms

SLC 3010, SLC-3010

Target

IL-2R

Action

agonists

Mechanism

IL-2R agonists(Interleukin-2 receptor agonists)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Metastatic Clear Cell Renal Cell Carcinoma

Inactive Indication

Advanced Malignant Solid Neoplasm

Originator Organization

Selecxine, Inc. Co Ltd.

Active Organization

Yonsei University

Inactive Organization

Selecxine, Inc. Co Ltd.

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

"This study is a phase 2, randomized study to evaluate the efficacy and safety of SLC-3010 in combination with axitinib versus axitinib monotherapy as second-line treatment in patients with locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).
This study includes a screening period, a treatment period, and a follow-up period. All patients will complete a screening period of up to 28 days. During the treatment period, patients will receive either SLC-3010 in combination with axitinib or axitinib monotherapy. Treatment may continue until the occurrence of unacceptable toxicity related to the study intervention, patient refusal for further participation, or disease progression.
The patients will be followed up for disease progression and survival for up to 2 years after discontinuation of the study intervention, or until death, consent withdrawal, or the end of this clinical trial, whichever occurs first. For patients who withdraw consent, survival will be followed up via telephone or site visits every 2 months up to death or 12 months after the first administration of the last patient, whichever occurs first, depending on their consent for follow-up.
This study consists of two parts: Part 1 is the safety run-in phase for SLC-3010 in combination with axitinib, and Part 2 is a randomized phase 2 trial to compare SLC-3010 in combination with axitinib and axitinib monotherapy.

Start Date01 Mar 2026

Sponsor / Collaborator

Yonsei University

NCT05525247

/ TerminatedPhase 1/2

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination With Various Anticancer Therapies in Patients With Advanced Solid Tumors

This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.

Start Date21 Dec 2022

Sponsor / Collaborator

Selecxine, Inc. Co Ltd.

100 Clinical Results associated with SLC-3010

Login to view more data

100 Translational Medicine associated with SLC-3010

Login to view more data

100 Patents (Medical) associated with SLC-3010

Login to view more data

12

News (Medical) associated with SLC-3010

20 May 2026

·selecxine.com

[POSTER] AACR 2025: A novel triple action of SLC-3010 strengthens anti-tumor immunity by in vivo free TCB2/endogenous IL-2 complexing

Abstract To induce favorable anti-tumor immune responses even after primary CD122-biased signaling, we developed SLC-3010, which is a non-covalent complex consisting of IL-2 and an anti-human IL-2 antibody (TBC2), conjugated through antigen-antibody interactions. Since TCB2 binds with IL-2 through CD25-binding epitope, the SLC-3010 provides CD122-biased signaling. Allthough the primary MoA, anti-tumor efficacy and crystal structure of SLC-3010 have been previously reported, the fate and physiological implications of the noncovalently conjugated drug, especially free TCB2, are not yet fully understood. We expected that free TCB2 can contribute to additional antitumor immune responses because TCB2 has a specific binding ability for IL-2 and can provide CD122-biased signaling when complexed with IL-2. Based on the TCB2 functionality, we hypothesize that free TCB2 suppress the Treg proliferation by intercepting IL-2 produced by effector T cells (Secondary MoA) and re-activates CD8 T and NK cells through CD122 biased signaling upon complexed with lately encountered IL-2. (Tertiary MoA)

11 May 2026

·selecxine.com

[PRESS] Selecxine Presents Next-Generation IL-2 Strategy Leveraging Alpha-Chain (CD25) Engagement

Selecxine Presents SLC-3010 Preclinical Data at AACR 2026 Selecxine presented preclinical data for its IL-2-based immuno-oncology candidate, SLC-3010, at the 2026 Annual Meeting of the American Association for Cancer Research (AACR), held in San Diego from April 17 to 22. SLC-3010 is a non-covalent IL-2/anti-IL-2 antibody complex designed to modulate immune signaling and enhance anti-tumor immune responses, while addressing limitations associated with conventional IL-2 therapies, including non-selective T-cell activation and regulatory T-cell (Treg) expansion. According to the company, the candidate incorporates a CD122-biased signaling profile while maintaining conditional CD25 accessibility, aiming to selectively activate antigen-experienced CD8 T cells within the tumor microenvironment. Preclinical findings presented at AACR showed that SLC-3010 induced immune activation in CD25-positive CD8 T cells and demonstrated anti-tumor activity in humanized IL-2 mouse models, along with modulation of CD8 T-cell and Treg populations in tumor microenvironment analyses. Selecxine also highlighted its ongoing clinical development strategy, including investigator-initiated Phase II studies across multiple solid tumor indications, such as renal cell carcinoma, biliary tract cancer, and gastric cancer. The company noted that further clinical evaluation is ongoing, with a focus on combination strategies with existing standard-of-care therapies. Original Article: https://www.koreahealthlog.com/news/articleView.html?idxno=57091

26 Nov 2025

·selecxine.com

Selecxine Highlights Open Innovation Collaboration at HLB Group’s 1st Pitch Day

Selecxine Highlights Open Innovation Collaboration and Global Competitiveness at HLB Group’s 1st Pitch Day Selecxine participated in the 1st Pitch Day hosted by HLB Group, where six biotech companies presented the outcomes of collaborative projects. During the event, Selecxine highlighted its proprietary “Selectope” platform, which selectively binds to specific epitopes of target proteins, and emphasized its global clinical competitiveness through the development of innovative antibody pipelines, including the novel immuno-oncology candidate SLC-3010 with a differentiated mechanism of action. Original Article: https://www.hitnews.co.kr/news/articleView.html?idxno=71347

100 Deals associated with SLC-3010

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic Clear Cell Renal Cell Carcinoma	Phase 2	South Korea	Yonsei University	01 Mar 2026
Advanced Malignant Solid Neoplasm	Phase 2	United States	Selecxine, Inc. Co Ltd.	21 Dec 2022
Advanced Malignant Solid Neoplasm	Phase 2	Australia	Selecxine, Inc. Co Ltd.	21 Dec 2022
Advanced Malignant Solid Neoplasm	Phase 2	South Korea	Selecxine, Inc. Co Ltd.	21 Dec 2022